PRNewswire-PRWeb October 14, 2025
HepQuant Announces Exciting New Data Utilizing HepQuant DuO® testing: Early Assessment of Resmetirom Treatment Benefit in Patients with Compensated MASH Cirrhosis
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, announces promising findings from a study utilizing the HepQuant DuO test to evaluate the impact of resmetirom treatment in patients with metabolic dysfunction-associated steatohepatitis (MASH)-related Child-Pugh A cirrhosis. In the peer-reviewed publication, 83% of patients showed either stability or improvement in liver function, as measured by DSI, after 48 weeks.
PRNewswire-PRWebOctober 2, 2025
HepQuant Presents a New Application for the HepQuant DuO™ Test: Improved Study Design and Treatment Monitoring in Clinical Trials
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, presented promising data utilizing the HepQuant DuO™ test to quantify liver function and physiology at an oral presentation on September 30, 2025 during the 9th Annual MASH Drug Development Summit in Boston, MA. Dr. Gregory T. Everson shared exciting data on the use of the HepQuant DuO test as a reasonably likely surrogate endpoint for clinical trials, highlighting this valuable tool in evaluating patients and planning studies.In The News
September 10, 2025
HepQuant DuO™ Estimates Risk for Clinical Outcome and Quantifies Changes in Risk
Dr. Greg Everson just shared groundbreaking insights at the Liver Forum in Paris! His presentation highlights how HepQuant DuO™ helps estimate clinical risk and track changes over time — a major step forward in liver disease management. [View his presentation here.]
April 23, 2025